Project Grant R01AI192662
- The Project Grant award of $189,376 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) supports research to unravel the interactions between skin microbiota and the immune system that drive early-life commensal tolerance. The research aims to better understand the mechanisms by which conserved microbial signals, specifically those recognized by Toll-like Receptor 2 (TLR2), promote the...
- The University of California, Davis received a $126,738 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on May 29, 2025. The grant supports research to investigate extramedullary granulopoiesis and immune responses in human skin using a novel skin-on-a-chip model. The project aims to provide mechanistic insight into the migration of hematopoietic stem and progenitor cells into human skin and their role in...
- This Project Grant award of $797,735 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research CFDA program, aims to elucidate the innate and adaptive immune mechanisms governing neonatal immune responses and sterile inflammation in early life. The research project will utilize a novel mouse model of allergen-induced neonatal sterile inflammation to investigate heightened innate and adaptive immune responses in neonates compared to...
- This federal Project Grant award for $243,950.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports a series of research aims to develop prognostic models for predicting the long-term course of atopic dermatitis (persistent disease and comorbidities) in diverse global settings, including cohorts from Uganda, Ecuador, and the United Kingdom....
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $401,191 Project Grant to The Johns Hopkins University on June 11, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The project aims to characterize the neonatal nasal microbiome following a parent-to-child nasal microbiota transplant, with the goal of developing interventions to prevent life-threatening Staphylococcus aureus infections in neonates. The research focuses on...
- The University of California, San Diego (UCSD) was awarded a $3,194,992.00 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, awarded on July 16, 2025, supports research to study the roles and regulation of tissue-resident CD8 T cells during a persistent viral infection. The research aims to investigate the mechanisms that allow immune cells to adapt and maintain a long-term...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $891,678 to the Scripps Research Institute in La Jolla, CA to conduct research on how metabolites from the intestinal microbiota can modulate host immune responses. The researchers will employ chemical biology and proteomics methods to identify specific microbiota-associated bile acid protein targets in mammalian cells...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $769,366 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The grant, effective from February 1, 2025 to January 31, 2030, aims to decipher the ontogeny of CD4+ resident memory T cells that globally seed the skin and protect against cutaneous leishmaniasis. The...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, awarded a $414,368 Project Grant to the University of California, Davis. The grant supports research to characterize the impact of postnatal early-life exposure to house dust mite and ozone on the lung epigenome and explore the mechanistic link between these changes and alveolar development and airway remodeling. The project aims to leverage collected...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) provides $198,782 to Duke University to develop a platform that leverages 3D human reconstructed epidermis (RHE) cultures to investigate interactions between the skin microbiome and skin cell populations. The goal is to enable the investigation of host-microbe interactions at a large scale by knocking out human genes...
This Project Grant award, titled "Skin Microbes and Development of Allergic Disease," is funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $5,176,858 award will support research at the University of California, San Diego (UCSD) to investigate how colonization by specific strains of Streptococcus bacteria that can damage the skin barrier may increase the risk of developing allergic diseases such as atopic dermatitis and food allergy in children. The 4-year project, beginning on September 5, 2025 and ending on August 31, 2029, will analyze approximately 6,000 skin swabs collected from the SUNBEAM Early Life Study to identify bacterial genes responsible for damaging or protective functions on the skin microbiome. Metagenomic and metabolomic analyses will further clarify the composition and actions of the skin microbiome and its impact on the immune system. This research aims to provide essential information to better understand how the skin microbiome influences the onset of allergic diseases in early life.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $5.2m | 9/5/25 |